Fig. 4

Diabetic patients with CTLI treated with auto-BM-MNC, or allo-WJ-MSCs, exhibited satisfactorily wound closure of the affected limb. The percentage of wound closure in participants treated with auto-BM-MNC or allo-WJ-MSCs was higher than in those treated with the placebo solution starting from the first month of the cell-based therapy, compared to the placebo group. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group one month post-treatment (ξ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group one month post-treatment (ϖ) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group three months post-treatment (λ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group three months post-treatment (ϕ) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group six months post-treatment (@) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group six months post-treatment (φ) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group twelve months post-treatment (Λ) (p < 0.05) and allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group twelve months post-treatment (Ω) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells